Circulating tumor DNA in head and neck cancer

About the Study: Liquid biopsy targeting viral ctDNA is a promising biomarker in the diagnostic and surveillance settings across head and neck cancer types. Ongoing clinical trials will help elucidate how ctDNA can be implemented to monitor treatment response, assess MRD, and frame treatment decisions to adapt treatment via a precision oncology approach.

Corresponding Author: Sagar Kansara, MD, Department of Otolaryngology–Head and Neck Surgery, Louisiana State University Health Sciences Center, 533 Bolivar St, Ste 566, New Orleans, LA 70112 (skans1@lsuhsc.edu).

10.1001/jamaoto.2026.2045

To access the embargoed study: Visit our JAMA Network Media Center website at this link https://media.jamanetwork.com/

Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2026.2045?guestAccessKey=5f1858b4-c218-4b29-acae-847dfba71724&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=073026

Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.